case_images: PMC10754991_01
case_images: Clinical course after admission. NMOSD was managed without relapse using four rounds of intravenous methylprednisolone therapy (IVMP, 1,000 mg/day for 3 days), monthly intravenous immunoglobulin therapy (IVIg, 400 mg/kg/day for 5 days), oral prednisolone (PSL), and azathioprine (AZA). However, the patient experienced steroid-related side effects including moon face and weight gain, prompting early PSL tapering. With a desire for pregnancy and prioritizing disease stability, satralizumab was introduced from day 110 after onset (initial dose of 120 mg subcutaneously, followed by injections after 2 and 4 weeks, and subsequently every 4 weeks). A positive pregnancy test occurred on day 140, and normal parturition took place on day 380. Both mother and infant remained healthy, with normal growth and development. Breastfeeding continued until 10 months after birth. Over 2 years and 6 months, a total of 34 doses of satralizumab were administered without relapse, and the PSL dosage was reduced to 8 mg/day.
case_images: fneur-14-1322412-g0001.jpg
case_images: PMC10754991_01_fneur-14-1322412-g0001.jpg
case_images: F1
case_images: A total of 34 doses of satralizumab were administered over 2 years and 6 months, during which there were no relapses, and the PSL dosage was reduced to 8 mg/day (Figure 1).